| Chronic Kidney Disease |
1 |
1 |
| Renal Failure |
0 |
0.95 |
| Kidney |
0 |
0.93 |
| Renal Disease |
0 |
1 |
| End-Stage Renal Disease |
0 |
0.76 |
| Type 2 Diabetes Mellitus |
0 |
1 |
| Cardiovascular Risk Management |
0 |
0.2 |
| GLP-1 Receptor Agonist |
0 |
0.7 |
| Receptors |
0 |
0.11 |
| Hemoglobin A1c |
0 |
0.8 |
| Clinical Research |
0 |
0.07 |
| Healthcare and Medical Technology |
0 |
0.07 |
| Hemoglobin |
0 |
0.07 |
| Blood |
0 |
0.04 |
| Cardiovascular disease |
0 |
0.04 |
| Clinical Pharmacology |
0 |
0.04 |
| Drug Costs |
0 |
0.04 |
| Epidemiology |
0 |
0.04 |
| Fellowship |
0 |
0.04 |
| Food and Drug Administration (FDA) |
0 |
0.04 |
| Hypoglycemia |
0 |
0.04 |
| SGLT2 Inhibitor |
0 |
0.6 |
| Washington |
0 |
0.04 |